Thomas Beetham
Geschäftsführer bei VIRIDIAN THERAPEUTICS, INC.
Vermögen: - $ am 30.04.2024
Aktive Positionen von Thomas Beetham
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
VIRIDIAN THERAPEUTICS, INC. | Geschäftsführer | 30.10.2023 | - |
Karriereverlauf von Thomas Beetham
Ehemalige bekannte Positionen von Thomas Beetham
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
DIANTHUS THERAPEUTICS, INC. | General Counsel | 01.06.2021 | 01.09.2023 |
Unternehmenssekretär | 01.06.2021 | 01.09.2023 | |
MAGENTA THERAPEUTICS | General Counsel | 14.06.2021 | 01.09.2023 |
Unternehmenssekretär | - | 14.06.2021 | |
KINIKSA PHARMACEUTICALS, LTD. | Geschäftsführer | 15.11.2019 | 01.06.2021 |
Gründer | 01.07.2015 | 01.06.2021 | |
General Counsel | 01.07.2015 | 01.06.2021 | |
Unternehmenssekretär | 01.12.2015 | 01.06.2021 | |
SYNAGEVA BIOPHARMA CORP | General Counsel | 01.10.2013 | 01.06.2015 |
New England Biolabs, Inc.
New England Biolabs, Inc. Chemicals: SpecialtyProcess Industries New England Biolabs, Inc. produces and supplies reagents for the life science industry. The firm?s products include restriction endonucleases, PCR, qPCR and amplification technologies, DNA modifying enzymes, sample preparation for next generation sequencing, nucleic acid purification, DNA assembly, cloning and mutagenesis kits, genome editing, competent cells, markers and ladders, RNA reagents, gene expression, cellular analysis, epigenetics, protein tools, DNA plasmids, glycobiology, protein expression and purification technologies. The company was founded by Donald Comb in 1974 and is headquartered in Ipswich, MA. | General Counsel | 01.10.2011 | 01.10.2013 |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | 01.09.2004 | 01.10.2011 |
Palmer & Dodge LLP | Corporate Officer/Principal | 01.09.1999 | 01.09.2004 |
Ausbildung von Thomas Beetham
Rochester Christian University | Undergraduate Degree |
Wallace E Carroll School of Management | Masters Business Admin |
Boston College Law School | Graduate Degree |
Statistik
International
Vereinigte Staaten | 11 |
2 |
Operativ
General Counsel | 5 |
Corporate Secretary | 3 |
Chief Operating Officer | 2 |
Sektoral
Health Technology | 6 |
Consumer Services | 4 |
Process Industries | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
KINIKSA PHARMACEUTICALS, LTD. | Health Technology |
VIRIDIAN THERAPEUTICS, INC. | Health Technology |
Private Unternehmen | 6 |
---|---|
Synageva BioPharma Corp.
Synageva BioPharma Corp. BiotechnologyHealth Technology Synageva BioPharma Corp. is a biopharmaceutical company which focuses on the discovery, development, and commercialization of therapeutic products for patients with life-threatening rare diseases and high unmet medical need. The company is currently evaluating sebelipase alfa in global clinical trials for LAL Deficiency, a lysosomal storage disease associated with liver damage and accelerated atherosclerosis in children and adults, and in infants, premature death often before six months of age. Synageva BioPharma was founded in 1993 and is headquartered in Lexington, MA. | Health Technology |
New England Biolabs, Inc.
New England Biolabs, Inc. Chemicals: SpecialtyProcess Industries New England Biolabs, Inc. produces and supplies reagents for the life science industry. The firm?s products include restriction endonucleases, PCR, qPCR and amplification technologies, DNA modifying enzymes, sample preparation for next generation sequencing, nucleic acid purification, DNA assembly, cloning and mutagenesis kits, genome editing, competent cells, markers and ladders, RNA reagents, gene expression, cellular analysis, epigenetics, protein tools, DNA plasmids, glycobiology, protein expression and purification technologies. The company was founded by Donald Comb in 1974 and is headquartered in Ipswich, MA. | Process Industries |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
Palmer & Dodge LLP | Commercial Services |
Magenta Therapeutics, Inc.
Magenta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Magenta Therapeutics, Inc. is a biotechnology company, which focuses on improving stem cell transplantation. Its platform includes MGTA-117, MGTA-145, and CD45-ADC. The company was founded by David T. Scadden, Derrick J. Rossi, Alan Tyndall, Luigi Naldini, Robert Negrin, John F. Dipersio, and Jason Gardner on June 17, 2015 and is headquartered in Cambridge, MA. | Health Technology |
Dianthus Therapeutics, Inc. |
- Börse
- Insiders
- Thomas Beetham
- Erfahrung